Vivos Therapeutics Partners with Florida Cardiology Group to Expand Sleep Apnea Treatment Access
Event summary
- Vivos Therapeutics has entered a collaboration agreement with South Palm Cardiovascular Associates (SPCVA) to form AIM Florida, a management services organization focused on treating sleep apnea and insomnia in cardiovascular patients.
- Vivos expects to hold at least 80% of AIM Florida, with SPCVA holding up to 20%, targeting initial operations in Palm Beach County, Florida.
- The model, based on Vivos' 2025 acquisition of Sleep Centers of Nevada, aims to serve 250 patients per month, generating over $6 million annually with 50% contribution margins.
- SPCVA, a multi-location cardiology practice with 30,000 patients, seeks to address the link between cardiovascular disease and obstructive sleep apnea (OSA).
- The collaboration is designed to comply with healthcare laws, including the Anti-Kickback Statute and physician self-referral rules.
The big picture
This collaboration aligns with Vivos' strategy of expanding access to sleep apnea treatment through partnerships rather than acquisitions, leveraging its existing model from Sleep Centers of Nevada. The move underscores the growing recognition of the link between cardiovascular disease and OSA, a trend that could drive demand for integrated diagnostic and treatment services. With over 2,500 cardiology groups in the U.S., the potential for scaling this model is significant, though execution risks remain.
What we're watching
- Scalability
- Whether Vivos can replicate this model with other cardiology groups across the U.S., given the fragmented nature of the cardiology market.
- Regulatory Compliance
- How AIM Florida navigates healthcare regulations, particularly the Anti-Kickback Statute, while maintaining clinical autonomy.
- Financial Performance
- The pace at which AIM Florida achieves its projected $6 million annual revenue and 50% contribution margins, and whether additional teams can be added efficiently.
Related topics